EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Von Hippel-Lindau syndrome: clinical features, genetic foundations, and management strategies

Emirhan Harbi, Michael Aschner

Molecular Biology Reports · 2025-12 · 52 (1)

DOI: 10.1007/s11033-025-10403-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Biology Reports, online erschienen am 05.03.2025. Verfasst von Emirhan Harbi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Pharmacology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY, 10461, USA. emirhanharbi41@gmail.com. Hauptthemen laut MEDLINE: von Hippel-Lindau Disease, Von Hippel-Lindau Tumor Suppressor Protein. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 68 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Von Hippel-Lindau Syndrome (VHL) is a rare, hereditary disorder characterized by the development of multiple tumors and cysts in various parts of the body due to mutations in the VHL gene on chromosome 3p25-26. Patients with VHL are at increased risk for hemangioblastomas of the brain, spinal cord, and retina, renal cell carcinomas, pheochromocytomas, pancreatic neuroendocrine tumors, and endolymphatic sac tumors. Clinical manifestations vary widely, and early diagnosis through genetic testing and regular surveillance is crucial for effective management. Treatment involves monitoring for tumor development, surgical removal of tumors, and targeted therapies for advanced cases. Recent advances in understanding the VHL pathway have led to new targeted treatments, particularly those involving the hypoxia-inducible factors and vascular endothelial growth factor pathways, which have improved patient outcomes. This article reviews the clinical features, genetic foundations, genotype/phenotype relationship and current management strategies for VHL, emphasizing recent advances that have enhanced prognosis and quality of life for patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

von Hippel-Lindau DiseaseVon Hippel-Lindau Tumor Suppressor ProteinHumansMutationGenetic TestingHemangioblastomaGenetic Predisposition to DiseaseQuality of Life

Stichwörter der Autor:innen

Hereditary Cancer syndromesOncogenesisTumor surveillanceVHL geneVon Hippel-Lindau syndrome

Substanzen

Von Hippel-Lindau Tumor Suppressor ProteinVHL protein, human

Autor:innen und Institutionen

  • Department of Molecular Pharmacology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY, 10461, USA. emirhanharbi41@gmail.com.
  • Department of Molecular Pharmacology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY, 10461, USA.

Zitieren

APA

Harbi, E., & Aschner, M. (2025). Von Hippel-Lindau syndrome: clinical features, genetic foundations, and management strategies. Molecular Biology Reports, 52(1). https://doi.org/10.1007/s11033-025-10403-8

Vancouver

Harbi E, Aschner M. Von Hippel-Lindau syndrome: clinical features, genetic foundations, and management strategies. Molecular Biology Reports. 2025;52(1). doi:10.1007/s11033-025-10403-8

BibTeX
@article{Harbi2025,
  author = {Harbi, Emirhan and Aschner, Michael},
  title = {Von Hippel-Lindau syndrome: clinical features, genetic foundations, and management strategies},
  journal = {Molecular Biology Reports},
  year = {2025},
  volume = {52},
  number = {1},
  doi = {10.1007/s11033-025-10403-8}
}
Kostenlos starten →